Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01969695 · ClinicalTrials.gov registry record · Phase 1
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01969695 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 11 participants.
The verdict
NCT01969695, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma \[CLL\], small lymphocytic lymphoma \[SLL\], and mantle cell lymphoma \[MCL\]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 when the study was completed, may roll over into this extension study. Subjects will receive ABT-199 during this study.
Interventions
- DRUG ABT-199
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-12-20 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01969695
The ClinicalTrials.gov registry entry for NCT01969695 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT-199 is the first listed.
NCT01969695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01969695 about?
NCT01969695 is a clinical study titled "An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma". This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma \[CLL\], small lymphocytic lymphoma \[SLL\], and mantle cell lymphoma \[MCL\]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 w...
What is the current status of trial NCT01969695?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2013-12-20. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT01969695?
The interventions under investigation include: ABT-199 (DRUG).
Who is sponsoring clinical trial NCT01969695?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.